Brief: GSK Canada & Pan-Canadian Pharmaceutical Alliance Sign LOI For Blenrep For A Type Of Multiple Myeloma
22/09/2026 12:03
BRIEF-GSK Canada & Pan-Canadian Pharmaceutical Alliance Sign LOI For Blenrep For A Type Of Multiple Myeloma Sept 22 (Reuters) - GSK Canada:
GSK CANADA AND THE PAN-CANADIAN PHARMACEUTICAL ALLIANCE SIGN LETTER OF INTENT FOR BLENREP FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA
GSK CANADA: PATIENTS TO GAIN PUBLICLY FUNDED ACCESS TO BLENREP AS TREATMENT OPTION FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
Source text: ID:nCNWPtxpba
Further company coverage: GSK.L
((Reuters.Briefs@thomsonreuters.com;))